Division of Dermatology, Department of Internal Medicine, Dell Medical School at The University of Texas at Austin.
Zitelli and Brodland Skin Cancer Center, Pittsburgh, Pennsylvania.
JAMA Dermatol. 2022 Aug 1;158(8):919-922. doi: 10.1001/jamadermatol.2022.1802.
Little is known about the association between insurance type and tumor or treatment characteristics among patients undergoing Mohs micrographic surgery (MMS) for nonmelanoma skin cancer (NMSC).
To investigate whether there are differences in tumor and treatment characteristics among patients undergoing MMS for NMSC by insurance type.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients with NMSC who presented for surgery at an academic MMS practice between May 2017 and May 2019.
Preoperative and postoperative tumor diameters, number of MMS stages, type of closure, and number of high-risk tumors were compared based on insurance type among uninsured and underinsured patients and those with private insurance, Medicare, and Veterans Affairs (VA) insurance.
A total of 1397 patients with NMSC (978 [70%] male; mean [SD] age, 68.5 [12.4] years) underwent 1916 MMS procedures. Of these patients, 868 (45%) had Medicare, 570 (30%) had private insurance, 299 (16%) had VA insurance, and 179 (9%) were treated at a safety net clinic or were uninsured. Compared with patients with private insurance, uninsured and underinsured patients had significantly larger preoperative tumor bed diameters (difference, 28%; 95% CI, 14%-43%; P < .001) and postoperative defect sizes (difference, 28%, 95% CI, 16%-41%; P < .001). Patients with Medicare and VA insurance did not have significantly different preoperative tumor bed diameters compared with patients with private insurance. Patients with VA insurance had larger postoperative defect sizes than patients with private insurance (difference, 12%; 95% CI, 2%-23%; P = .02). The number of MMS stages and type of closure did not significantly differ based on insurance type.
In this cohort study of patients undergoing MMS for NMSC, larger preoperative tumor and postoperative defect sizes were associated with being uninsured or underinsured compared with privately insured. Future studies are required to determine why these differences exist to deliver optimal care to all patients.
对于接受 Mohs 显微外科手术(MMS)治疗非黑色素瘤皮肤癌(NMSC)的患者,保险类型与肿瘤或治疗特征之间的关联知之甚少。
研究接受 MMS 治疗 NMSC 的患者中,保险类型是否会影响肿瘤和治疗特征。
设计、地点和参与者:这是一项回顾性队列研究,纳入 2017 年 5 月至 2019 年 5 月在学术 MMS 实践中接受手术的 NMSC 患者。
在未参保和参保不足的患者以及有私人保险、医疗保险和退伍军人事务(VA)保险的患者中,根据保险类型比较术前和术后肿瘤直径、MMS 分期数、闭合类型和高危肿瘤数。
共有 1397 例 NMSC 患者(978[70%]为男性;平均[SD]年龄 68.5[12.4]岁)接受了 1916 次 MMS 手术。其中 868 例(45%)有医疗保险,570 例(30%)有私人保险,299 例(16%)有 VA 保险,179 例(9%)在安全网诊所治疗或未参保。与私人保险患者相比,未参保和参保不足的患者术前肿瘤床直径明显更大(差异为 28%,95%CI,14%-43%;P<0.001),术后缺损也更大(差异为 28%,95%CI,16%-41%;P<0.001)。医疗保险和 VA 保险患者的术前肿瘤床直径与私人保险患者相比无显著差异。VA 保险患者的术后缺损比私人保险患者大(差异为 12%,95%CI,2%-23%;P=0.02)。MMS 分期数和闭合类型在不同保险类型之间无显著差异。
在这项针对接受 MMS 治疗 NMSC 的患者的队列研究中,与私人保险患者相比,未参保或参保不足的患者术前肿瘤和术后缺损较大。需要进一步研究以确定这些差异存在的原因,以便为所有患者提供最佳护理。